116 related articles for article (PubMed ID: 23902971)
1. Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine.
Uramatsu T; Nishino T; Obata Y; Sato Y; Furusu A; Koji T; Miyazaki T; Kohno S
Biol Pharm Bull; 2013; 36(8):1271-7. PubMed ID: 23902971
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effect of azelnidipine in rats.
Kurashige T; Abe K; Furusu A; Miyazaki M; Obata Y; Xia Z; Nakazawa M; Nakazawa Y; Funakoshi S; Harada T; Koji T; Kohno S
Biol Pharm Bull; 2008 Dec; 31(12):2237-44. PubMed ID: 19043206
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Shinohara K; Hirooka Y; Ogawa K; Kishi T; Yasukawa K; Utsumi H; Sunagawa K
Clin Exp Hypertens; 2012; 34(6):456-62. PubMed ID: 22471901
[TBL] [Abstract][Full Text] [Related]
4. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Noda K; Hosoya M; Nakajima S; Ohashi J; Fukumoto Y; Shimokawa H
Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
[TBL] [Abstract][Full Text] [Related]
5. Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.
Guo Q; Minami N; Mori N; Nagasaka M; Ito O; Kurosawa H; Kanazawa M; Kohzuki M
Hypertens Res; 2008 Mar; 31(3):525-33. PubMed ID: 18497473
[TBL] [Abstract][Full Text] [Related]
6. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
Hosoya M; Ohashi J; Sawada A; Takaki A; Shimokawa H
Circ J; 2010 Apr; 74(4):798-806. PubMed ID: 20154404
[TBL] [Abstract][Full Text] [Related]
8. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
9. Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.
Omote Y; Deguchi K; Kono S; Liu W; Kurata T; Hishikawa N; Yamashita T; Ikeda Y; Abe K
J Neurosci Res; 2014 Oct; 92(10):1330-7. PubMed ID: 24839960
[TBL] [Abstract][Full Text] [Related]
10. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Konno S; Hirooka Y; Araki S; Koga Y; Kishi T; Sunagawa K
J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
[TBL] [Abstract][Full Text] [Related]
11. Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats.
Rafiq K; Nishiyama A; Konishi Y; Morikawa T; Kitabayashi C; Kohno M; Masaki T; Mori H; Kobori H; Imanishi M
PLoS One; 2014; 9(9):e107853. PubMed ID: 25233358
[TBL] [Abstract][Full Text] [Related]
12. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
[TBL] [Abstract][Full Text] [Related]
13. Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.
Kim-Mitsuyama S; Izumi Y; Izumiya Y; Yoshida K; Yoshiyama M; Iwao H
Hypertens Res; 2004 Oct; 27(10):771-9. PubMed ID: 15785013
[TBL] [Abstract][Full Text] [Related]
14. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M
Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
[TBL] [Abstract][Full Text] [Related]
15. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
[TBL] [Abstract][Full Text] [Related]
16. Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation.
Lu H; Kanazawa M; Ishida A; Tufescu A; Sasaki Y; Ito O; Kurosawa H; Sato T; Ootaka T; Kohzuki M
Am J Hypertens; 2009 Oct; 22(10):1101-6. PubMed ID: 19730414
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation.
Kanazawa M; Kohzuki M; Yoshida K; Kurosawa H; Minami N; Saito T; Yasujima M; Abe K
Hypertens Res; 2002 May; 25(3):447-53. PubMed ID: 12135325
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
Tanifuji C; Suzuki Y; Geot WM; Horikoshi S; Takahashi H; Tomino Y
Kidney Blood Press Res; 2009; 32(4):239-49. PubMed ID: 19752573
[TBL] [Abstract][Full Text] [Related]
19. Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.
Araki S; Hirooka Y; Kishi T; Yasukawa K; Utsumi H; Sunagawa K
Hypertens Res; 2009 Dec; 32(12):1091-6. PubMed ID: 19763130
[TBL] [Abstract][Full Text] [Related]
20. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
